Comparison Of Intrathecal Levobupivacaine Plus Nalbuphine Versus Levobupivacaine Plus Fentanyl For Lower Limb Orthopedic Surgery A Prospective Randomized Study - NIL

Start Date01 Apr 2626

Sponsor / Collaborator

State of Gujarat

NCT07837492

/ Not yet recruitingPhase 4IIT

Ultrasound-Guided Ilioinguinal-Iliohypogastric Nerve Block Following Spinal Anesthesia Comparing Dexmedetomidine Versus Nalbuphine as Adjuvants to Bupivacaine in Unilateral Inguinal Hernia Repair: A Prospective, Randomized, Double-Blind Controlled Study

This study evaluates and compares the pain-relieving efficacy and safety of adding either dexmedetomidine or nalbuphine to bupivacaine in an ultrasound-guided ilioinguinal-iliohypogastric nerve block for patients undergoing elective unilateral inguinal hernia repair under spinal anesthesia.
While spinal anesthesia provides effective surgical anesthesia, postoperative pain often increases as the block recedes. Supplementing spinal anesthesia with an ultrasound-guided peripheral nerve block targeting the ilioinguinal and iliohypogastric nerves provides localized pain relief. Adding adjuvant medications to the local anesthetic may extend the duration of pain control and reduce systemic analgesic requirements.
Participants are randomly allocated to one of three groups:
* Control Group: Receives bupivacaine with normal saline.
* Nalbuphine Group: Receives bupivacaine combined with nalbuphine.
* Dexmedetomidine Group: Receives bupivacaine combined with dexmedetomidine.
The primary objective is to assess the duration of analgesia by measuring the time from the regression of spinal sensory anesthesia until the first request for rescue pain medication. Secondary objectives include evaluating total 24-hour pain medication consumption, postoperative pain scores, vital signs, sedation scores, patient satisfaction, and side effects.

Start Date01 Oct 2026

Sponsor / Collaborator

Assiut University

ChiCTR2600132902

/ Not yet recruitingNot ApplicableIIT

Effects of different analgesics on postoperative nausea and vomiting during anesthesia for hysteroscopic surgery

Start Date01 Oct 2026

Sponsor / Collaborator-

100 Clinical Results associated with Nalbuphine Hydrochloride

100 Translational Medicine associated with Nalbuphine Hydrochloride

100 Patents (Medical) associated with Nalbuphine Hydrochloride

1,479

Literatures (Medical) associated with Nalbuphine Hydrochloride

01 Jan 2027·TALANTA

Machine learning-assisted photoelectrochemical aptasensor for nalbuphine monitoring using a BiOBr/SrWO4 S-scheme heterojunction

Article

Author: Liu, Jingyang ; Wang, YuanYuan ; Xiao, Yangjie ; Zhu, Ying ; Ma, Yan

Precise therapeutic drug monitoring is essential for optimizing nalbuphine treatment in uremic pruritus, yet rapid and sensitive analytical tools suitable for clinical application remain limited. Herein, we report a machine learning-guided photoelectrochemical (PEC) aptasensor for nalbuphine detection based on a BiOBr/SrWO₄ S-scheme heterojunction. Clinical data from 102 peritoneal dialysis patients were first analyzed using seven machine learning algorithms to identify determinants of therapeutic response. Gradient Boosting exhibited the best predictive performance, with an accuracy of 84.6%, a response recall of 83.3%, and an AUC of 0.868 on the independent test set, and nalbuphine dose emerged as the most influential variable, establishing the clinical need for accurate drug monitoring. Guided by this finding, a signal-on PEC aptasensor was constructed by integrating a BiOBr/SrWO₄ heterojunction photoactive interface with an NH₂-modified ssDNA aptamer for selective nalbuphine recognition. The optimized BiOBr/SrWO₄-40% composite displayed enhanced visible-light harvesting, suppressed charge recombination, and accelerated interfacial charge transfer. Ultraviolet photoelectron spectroscopy and density functional theory calculations further verified the S-scheme charge-transfer pathway and the built-in electric field-driven carrier separation mechanism. Under optimal conditions, the aptasensor exhibited a linear response toward nalbuphine from 0.01 to 1.2 μg mL^-1 with a limit of detection (LOD) of 3.5 ng mL^-1, along with good selectivity, stability, and reproducibility. In spiked serum samples, recoveries ranged from 96.05% to 99.59% with relative standard deviations below 5%. This work provides a clinically oriented strategy for integrating machine learning with PEC biosensing and offers a promising platform for personalized therapeutic drug monitoring.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Modulation of mu-opioid pathway for the treatment of pruritus: a systematic review of 1,146 patients

Review

Author: Abu Suleiman, Amro ; Ahmed, Khalid M. A. ; Alnajdawi, Alaa I. ; Moustafa, Ahmed R. A. ; Horton, Emma ; Ahmed, Ahmed M. ; Abdulkader, Dina

BACKGROUND:

Pruritus is a debilitating symptom and conventional therapies often provide incomplete relief. The μ-opioid receptor (MOR) pathway is a key regulator of itch, and μ-pathway-modulating agents are increasingly used off-label for refractory pruritus.

AIM:

This systematic review evaluates the efficacy, safety, and real-world use of μ-opioid pathway modulators for pruritus of dermatologic and systemic origin.

METHODS:

Following PRISMA guidelines (PROSPERO CRD420251207101), a comprehensive search of four databases identified 3,274 records, of which 69 studies met inclusion criteria, comprising 14 randomized controlled trials (RCTs; n = 795) and 55 non-randomized studies (n = 351). Owing to substantial clinical and methodological heterogeneity, findings were narratively synthesized.

RESULTS:

Five RCTs evaluated dermatologic conditions, including atopic dermatitis, prurigo nodularis, chronic urticaria, and lichen planopilaris, while nine RCTs assessed systemic pruritus, predominantly cholestatic and uremic pruritus. RCTs investigated oral or topical naltrexone, intravenous naloxone, nalmefene, and extended-release nalbuphine, with most demonstrating clinically meaningful reductions in pruritus intensity using validated itch scales. Non-randomized studies reported improvement across a wide range of dermatologic and systemic conditions, with adverse events generally mild and well tolerated.

CONCLUSIONS:

Overall, μ-opioid pathway modulators show promising efficacy with acceptable short-term safety across diverse pruritic conditions, although larger high-quality RCTs are required to define optimal dosing and support clinical translation.

01 Dec 2026·Current Pain and Headache Reports

Adjunct Medications for Single-Injection Pediatric Regional Blocks: Implications for Peripheral Nerve Blocks

Review

Author: Jha, Sachin Sunny

PURPOSE OF REVIEW:

Single-injection peripheral nerve blocks (PNBs) provide excellent perioperative analgesia in children but are limited by finite duration. Pediatric populations were excluded from the major adult adjunct reviews. This narrative review synthesizes the evidence for adjuncts added to local anesthetics for single-injection PNBs and caudal blocks in patients aged 0 to 18 years, including dexamethasone, dexmedetomidine, clonidine, conventional opioids, buprenorphine, magnesium sulfate, midazolam, ketamine, neostigmine, tramadol, nalbuphine, and epinephrine.

RECENT FINDINGS:

Across 58 studies, dexmedetomidine (0.5 to 1 mcg/kg) and dexamethasone (0.1 mg/kg perineural) were the best-supported agents, each roughly doubling analgesic duration with acceptable safety. Two network meta-analyses ranked neostigmine highest for caudal duration, but its postoperative nausea and vomiting burden limits use. Clonidine has the longest safety record. Ketamine and midazolam show robust caudal efficacy but unresolved neurotoxicity concerns. Nalbuphine and buprenorphine are promising but under-studied. Tramadol carries pediatric regulatory restrictions, while epinephrine and conventional opioids add little. Dexmedetomidine and dexamethasone are the preferred adjuncts in pediatric regional anesthesia. Adult evidence should not be extrapolated directly given developmental pharmacology and pediatric-specific safety considerations. Prospective trials in true pediatric PNBs and pediatric rebound-pain studies remain the critical evidence gaps.

146

News (Medical) associated with Nalbuphine Hydrochloride

03 Sep 2026

·www.globenewswire.com

Trevi Therapeutics to Participate in Upcoming September Conferences

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September. 2026 Cantor Global Healthcare ConferenceSeptember 9-11, 2026, New York, New YorkFireside Chat: September 10, 10:55 a.m. to 11:25 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFOTo register for the Fireside Chat virtually, click here. H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 14-16, 2026, New York, New York Fireside Chat (in-person): September 14, 9:00 a.m. to 9:30 a.m. ETTrevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO Morgan Stanley 24th Annual Global Healthcare ConferenceSeptember 14-16, 2026, New York, New York Fireside Chat: September 15, 4:50 p.m. to 5:25 p.m. ETTrevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDOTo register for the Fireside Chat virtually, click here. 10th Anniversary IPF SummitSeptember 29-October 1, 2026, Boston, Massachusetts Panel Discussions: October 1, 11:00 a.m. to 11:30 a.m. ET and 3:40 p.m. to 4:10 p.m. ETPanel 1: Which Patient-Reported Outcomes Should We Use in IPF Trials and Care to Ensure We’re Measuring What Matters to PatientsPanel 2: Translating Preclinical Combination Data into Clinical Development StrategyTrevi Representative: James Cassella, Ph.D., CDOTo register for the summit, click here. About Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life. RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn. Investor ContactJonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286IR@trevitx.com Media ContactRosalia Scampoli914-815-1465rscampoli@marketcompr.com

03 Sep 2026

·www.biospace.com

Trevi Therapeutics to Participate in Upcoming September 2026 Conferences

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in the following conferences in September. 2026 Cantor Global Healthcare Conference September 9-11, 2026, New York, New York Fireside Chat: September 10, 10:55 a.m. to 11:25 a.m. ET Trevi Representatives: Jennifer Good, President and CEO, and David Hastings, CFO To register for the Fireside Chat virtually, click here . H.C. Wainwright 28th Annual Global Investment Conference September 14-16, 2026, New York, New York Fireside Chat (in-person): September 14, 9:00 a.m. to 9:30 a.m. ET Trevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, Pharm.D., CCO Morgan Stanley 24th Annual Global Healthcare Conference September 14-16, 2026, New York, New York Fireside Chat: September 15, 4:50 p.m. to 5:25 p.m. ET Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, Ph.D., CDO To register for the Fireside Chat virtually, click here . ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); 10th Anniversary IPF Summit September 29-October 1, 2026, Boston, Massachusetts Panel Discussions: October 1, 11:00 a.m. to 11:30 a.m. ET and 3:40 p.m. to 4:10 p.m. ET Panel 1: Which Patient-Reported Outcomes Should We Use in IPF Trials and Care to Ensure We’re Measuring What Matters to Patients Panel 2: Translating Preclinical Combination Data into Clinical Development Strategy Trevi Representative: James Cassella, Ph.D., CDO To register for the summit, click here . About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life. RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially. ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit  and follow Trevi on  X  (formerly Twitter) and  LinkedIn . Investor Contact Jonathan Carlson Trevi Therapeutics, Inc. (203) 654 3286 IR@trevitx.com Media Contact Rosalia Scampoli 914-815-1465 rscampoli@marketcompr.com ezstandalone.cmd.push(function () { ezstandalone.showAds(133); });

Clinical Result

26 Aug 2026

·www.biospace.com

Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026

Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough Dr. Imran Satia will give a poster presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC NEW HAVEN, Conn., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the acceptance of two abstracts for presentation at the European Respiratory Society (ERS) Congress 2026 , taking place from September 5-9, 2026, in Barcelona, Spain. Abstract: Nalbuphine extended-release for chronic cough in patients with idiopathic pulmonary fibrosis: assessment of quality of life using the Leicester Cough Questionnaire in the Phase 2b CORAL trial Oral Presentation Session: 325 – Moving forward in interstitial lung disease: new data on novel therapies Date & Time: September 7, 11:00 a.m. to 12:15 p.m. CEST Location: 3K Oral Presenter: Marlies S. Wijsenbeek, MD, PhD Abstract: Quality of life outcomes assessed by the Leicester Cough Questionnaire in the Phase 2a RIVER trial of nalbuphine extended-release in refractory chronic cough Poster Session: 343 – Novel cough therapeutics: the airway microbiome Date & Time: September 7, 12:30 p.m. to 2:00 p.m. CEST Location: PS-15 Poster Presenter: Imran Satia, MB, BChir, PhD, MRCP Registration Details About the Phase 2b CORAL Trial The Phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) trial was a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of nalbuphine ER (27 mg, 54 mg, and 108 mg twice daily) compared to placebo for the treatment of chronic cough in patients with IPF over a 6-week treatment period. 165 patients with IPF chronic cough were randomized 1:1:1:1 to one of three nalbuphine ER dose groups or placebo with an initial 2-week titration period to the target dose followed by 4 weeks of fixed dosing. The primary efficacy endpoint for the trial was the relative change in 24-hour cough frequency (coughs per hour), as determined by an objective cough monitor, for the modified intent-to-treat (mITT) population at the end of Week 6 versus Baseline for nalbuphine ER compared to placebo. The mITT population consisted of all patients who were randomized and received at least one dose of study drug or placebo. About the Phase 2a RIVER Trial The Phase 2a Refractory Chronic Cough Improvement Via Nalbuphine ER (RIVER) trial was a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover study designed to evaluate the efficacy, safety, and tolerability of nalbuphine ER for the treatment of patients with RCC. Each treatment period lasted 21 days, separated by a 21-day washout period. During the nalbuphine ER treatment period, patients were titrated with assessments at 27 mg twice daily (BID), 54 mg BID, and 108 mg BID for objective cough and other assessments at each dose. The primary endpoint of the trial was the mean change in 24-hour cough frequency, as determined by an objective cough monitor, for the full analysis set (FAS) population at Day 21. The FAS population included all patients who received at least one dose of study drug and have objective cough count data on both Baseline and Day 21 in at least one treatment period. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life. RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn . Investor Contact Jonathan Carlson Trevi Therapeutics, Inc. (203) 654 3286  IR@trevitx.com Media Contact Rosalia Scampoli 914-815-1465 rscampoli@marketcompr.com

Phase 2Clinical Result

100 Deals associated with Nalbuphine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00843	Nalbuphine Hydrochloride	N02AF02	DB00844

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	United States	PH HEALTH	15 May 1979
Pain	United States	PH HEALTH	15 May 1979

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic cough	Phase 3	United States	Trevi Therapeutics, Inc.	29 Jun 2026
Idiopathic Pulmonary Fibrosis	Phase 3	United States	Trevi Therapeutics, Inc.	29 Jun 2026
Analgesia	Phase 3	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	09 Oct 2023
Respiratory Insufficiency	Phase 3	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	30 Aug 2023
prurigo nodularis	Phase 3	United States	Trevi Therapeutics, Inc.	01 Mar 2015
prurigo nodularis	Phase 3	Germany	Trevi Therapeutics, Inc.	01 Mar 2015
prurigo nodularis	Phase 3	Poland	Trevi Therapeutics, Inc.	01 Mar 2015
Pruritus	Phase 3	Germany	Trevi Therapeutics, Inc.	01 Mar 2015
Uremic pruritus	Phase 3	United States	Trevi Therapeutics, Inc.	01 Jun 2014
Uremic pruritus	Phase 3	Poland	Trevi Therapeutics, Inc.	01 Jun 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05964335 (CORAL, CTgov)	Phase 2	Cough \| Idiopathic Pulmonary Fibrosis \| Chronic cough	165	Placebo (Placebo)	gzdiprgdvd(dwmtaktlqg) = lvxtpzilqi koxzzlxznm (ifoqxieoec, 0.173) View more	-	26 Jun 2026
				NAL ER (NAL ER 27 mg)	gzdiprgdvd(dwmtaktlqg) = bmektvvvno koxzzlxznm (ifoqxieoec, 0.168) View more
NCT05964335 (CORAL, ATS2026)	Phase 2	Idiopathic Pulmonary Fibrosis	165	Nalbuphine Extended-release Tablets 27 mg BID	twyhaedgfh(zxsymhpmxk) = bchffpqrhw pvrncyjowq (rtowefilci )	Positive	15 May 2026
				Nalbuphine Extended-release Tablets 108 mg BID	twyhaedgfh(zxsymhpmxk) = vwpmeobgpu pvrncyjowq (rtowefilci )
NCT05964335 (CORAL, ATS2026)	Phase 2	Idiopathic Pulmonary Fibrosis	165	Nalbuphine ER 27mg BID	lzpsxzggdu(nokfnihstz) = lvgpsyniil ethtngjyts (wrefgjhflt )	Positive	15 May 2026
				Nalbuphine ER 54mg BID	-
NCT05962151 (RIVER, CTgov)	Phase 2	Refractory chronic cough	66	NAL (NAL ER)	bcnamsjipe(cutupnvdmw) = dglawokfvx vizekbdjgt (tfdqycpauz, 36.552) View more	-	30 Mar 2026
				placebo (Placebo)	bcnamsjipe(cutupnvdmw) = yltsgcsoia vizekbdjgt (tfdqycpauz, 40.952) View more
NCT04020016 (CTgov)	Phase 1	Pruritus	28	NAL ER (Cohort 1: NAL ER 27 mg)	eqwxmuhojk(jgnomixmil) = kdhlaalcqk pznolihcff (pcubljwydd, 41.8) View more	-	19 Mar 2026
				NAL ER (Cohort 2: NAL ER 54 mg)	eqwxmuhojk(jgnomixmil) = zuwjvqrjru pznolihcff (pcubljwydd, 38.9) View more
NCT05964335 (CORAL, Pubmed \| JAMA) Manual	Phase 2	Cough	160	Nalbuphine ER 27 mg	vvzslaguzn(pnzyklufdw) = tqvtwzgjah sneyjgmegk (pagnsdowdk ) View more	Positive	22 Jan 2026
				Nalbuphine ER 54 mg	vvzslaguzn(pnzyklufdw) = eqfmzktvlb sneyjgmegk (pagnsdowdk ) View more
NCT03497975 (PRISM \| PRISM study, CTgov)	Phase 2/3	prurigo nodularis \| Pruritus	353	Nalbuphine ER Tablets (NAL ER)	ppwaxfhymm = uiurgirbar edpcytcivj (dixfvavztd, dpbafwaizn - zxjptbaagy) View more	-	24 Jun 2025
				Placebo Tablets+Nalbuphine ER Tablets (Placebo)	ppwaxfhymm = zzuejhhfue edpcytcivj (dixfvavztd, nmntzmnwgj - vzhwlhwyzh) View more
NCT05962151 (RIVER, PRNewswire 1 \| PRNewswire 2) Manual	Phase 2	Refractory chronic cough	66	Haduvio (27 mg twice daily (BID), 54 mg BID and 108 mg BID)	bjrlibneyq(odukegnwcz) = mgvhckmnae bavclumdpg (wmijajxyhw ) Met View more	Positive	10 Mar 2025
				Placebo	bjrlibneyq(odukegnwcz) = qlflyomljr bavclumdpg (wmijajxyhw ) Met View more
PRNewswire Manual	Not Applicable	Chronic cough	-	Placebo	csdizbhykd(dxfcdfotoe) = pzvvcmvwhn jwitpktbsf (oiivbgrfla ) View more	Positive	03 Dec 2024
				IV Butorphanol 6mgButorphanol 6mg	csdizbhykd(dxfcdfotoe) = suvtmiogrq jwitpktbsf (oiivbgrfla ) View more
NCT02820051 (CTgov)	Not Applicable	Sedation	102	Transcutaneous CO2 monitor+Midazolam+Lidocaine+nalbuphine (Midazolam)	eisltddsou(qxtullubdi) = eaeyyvudho jvznpxvjnt (lmesfrinlh, 7.5) View more	-	02 Dec 2024
				Transcutaneous CO2 monitor+propofol+Lidocaine+nalbuphine (Propofol)	eisltddsou(qxtullubdi) = lxvjnrvrfd jvznpxvjnt (lmesfrinlh, 9.6) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis